-+ 0.00%
-+ 0.00%
-+ 0.00%

AngioDynamics Expects 2025 Net Sales Of $285M-$288M Compared To Prior Guidance Of $282M-$288M And Consensus Of $284.91M

Benzinga·04/02/2025 10:35:35
Listen to the news

Fiscal Year 2025 Financial Guidance

For fiscal year 2025:

  • The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.
  • The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%.
  • The Company continues to expect Med Device net sales to be flat.
  • The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%.
  • The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024.
     
Guidance Metric Guidance Action

Current Guidance

(As of Apr. 2, 2025)

Previous Guidance

(Issued on Jan. 8, 2025)

Net Sales Increased $285 - $288 million $282 - $288 million
Med Tech Net Sales Growth Increased 14 - 16% 12 - 15%
Med Device Net Sales Growth Unchanged Flat (unchanged) Flat
Gross Margin Increased 53 - 54% 52 - 53%
Adjusted EBITDA Increased $4.0 - $5.0 million $1.0 - $3.0 million
Adjusted EPS Increased ($0.31) - ($0.34) ($0.34) - ($0.38)